Full Answer
Will VXRT stock go back up?
During the day the stock fluctuated 5.68% from a day low at $4.58 to a day high of $4.84. The price has fallen in 6 of the last 10 days and is down by -10.9% for this period....Predicted Opening Price for Vaxart of Wednesday, April 13, 2022.Fair opening price April 13, 2022Current price$4.69$4.66 (Undervalued)
Is VXRT a good stock to buy now?
Vaxart has received a consensus rating of Buy.
Why is VXRT going up?
Shares of clinical-stage vaccine developer Vaxart ( VXRT 3.96% ) are up again today, gaining 12.34% to $9.83 apiece as of 2:30 p.m. EDT. The stock is up 21% over the past five trading days due to greater capital inflows after the company released encouraging second-quarter earnings on Aug. 5.Aug 9, 2021
Is VXRT a buy or sell?
Out of 4 analysts, 3 (75%) are recommending VXRT as a Strong Buy, 0 (0%) are recommending VXRT as a Buy, 1 (25%) are recommending VXRT as a Hold, 0 (0%) are recommending VXRT as a Sell, and 0 (0%) are recommending VXRT as a Strong Sell. What is VXRT's earnings growth forecast for 2022-2024?
Will VXRT stock go up tomorrow?
If this Munafa value is near or nearing 100, then this stock might show an upward movement....Munafa value: 40 as on 08 Fri Apr 2022.Downside target4.5Upside target4.79Upside target4.87Upside target4.88Upside target5.045 more rows
What is vaxart future?
According to the 4 industry analysts covering Vaxart, the consensus is that breakeven is near. They expect the company to post a final loss in 2022, before turning a profit of US$6.4m in 2023. The company is therefore projected to breakeven around 2 years from today.Sep 14, 2021
How do I buy VXRT stock?
Find the stock by name or ticker symbol – VXRT – and research it before deciding if it's a good investment for you. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price. Check in on your investment.
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices
When I first wrote about Vaxart (NASDAQ:VXRT) stock on Aug. 10, I was completely enamored by the clinical-stage biotech company’s attempts to bring an oral Covid-19 vaccine to the market.
Vaxart, Inc.'s (NASDAQ:VXRT) Shift From Loss To Profit
Vaxart, Inc. ( NASDAQ:VXRT ) is possibly approaching a major achievement in its business, so we would like to shine...
Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors
Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington, Ph.D., to the company's board of directors. Dr. Cherrington is an experienced life science executive with extensive insights into taking drugs through the development process to commercialization.
Vaxart Announces Creation of New Scientific and Clinical Advisory Board
Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board.
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Why Shares of Vaxart Are Soaring Today
Shares of clinical-stage vaccine developer Vaxart (NASDAQ: VXRT) are up again today, gaining 12.34% to $9.83 apiece as of 2:30 p.m. EDT. The stock is up 21% over the past five trading days due to greater capital inflows after the company released encouraging second-quarter earnings on Aug. 5.
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 7.14% and -79.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices
When I first wrote about Vaxart (NASDAQ:VXRT) stock on Aug. 10, I was completely enamored by the clinical-stage biotech company’s attempts to bring an oral Covid-19 vaccine to the market.
Vaxart, Inc.'s (NASDAQ:VXRT) Shift From Loss To Profit
Vaxart, Inc. ( NASDAQ:VXRT ) is possibly approaching a major achievement in its business, so we would like to shine...
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Why Shares of Vaxart Are Soaring Today
Shares of clinical-stage vaccine developer Vaxart (NASDAQ: VXRT) are up again today, gaining 12.34% to $9.83 apiece as of 2:30 p.m. EDT. The stock is up 21% over the past five trading days due to greater capital inflows after the company released encouraging second-quarter earnings on Aug. 5.
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 7.14% and -79.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Vaxart Stock Surged Today
Shares of Vaxart (Nasdaq: VXRT) rose on Monday after the biotech said the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for its oral coronavirus vaccine. As of 2:20 p.m. EDT, Vaxart's stock price was up more than 12%.
5 Top Stock Gainers for Monday: Square, Levi Strauss, Vaxart
Stocks rose Monday with solid corporate earnings and dealmaking lifting equities as Wall Street kicked off the first trading of August near all-time highs. Square shares climbed after the Twitter -backed payments company unveiled a $29 billion takeover of Australia's Afterpay and pre-announced stronger-than-expected second-quarter earnings.
Vaxart Media Sentiment
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
Media Coverage
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
Vaxart (NASDAQ VXRT) News Headlines Today
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
What is Operation Warp Speed?
Operation Warp Speed is a new national program aiming to provide substantial quantities of a safe, effective vaccine for Americans by January 2021. The program originally began when the White House selected 5 candidates in early June. They included candidates from Moderna, AstraZeneca, Johnson & Johnson, Merck, and Pfizer. Joining this prestigious list in June was VXRT stock with its oral COVID-19 vaccine. Vaxart will participate in a non-human primate (NHP) challenge study. The study is designed to demonstrate the efficacy of Vaxart’s oral COVID-19 vaccine candidate. Andrei Floroiu, Chief Executive Officer of Vaxart Inc, said:
Is VXRT stock bullish?
One of the many reasons to be bullish on VXRT stock is its COVID-19 Investigational New Drug (IND) application filed with the US FDA on Monday. This is the first step in advancing its oral COVID-19 vaccine candidate towards the clinic. This upcoming Phase I study will further differentiate Vaxart’s oral vaccine from injectable vaccines by substantiating the importance of activating both systemic and mucosal immunity in protecting against COVID-19.
Is VXRT stock preclinical?
VXRT stock just released preclinical data on its SARS-CoV-2 (COVID-19) vaccine based on Vaxart’s oral adenovirus platform. The data is available on an online preprint server at https://biorxiv.org/cgi/content/short/2020.09.04.283853v1. The findings showed:
A new study shows that there is a dire need for a vaccine of the kind Vaxart is developing
A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
What happened
Shares of Vaxart ( NASDAQ:VXRT) are up by 13.2% as of 11:14 a.m. EDT on Thursday, after the company announced the publication of a new study that estimates the annual cost of norovirus gastroenteritis in the U.S.
So what
Norovirus is a contagious virus that causes such symptoms as vomiting and diarrhea. According to this new study, outbreaks of norovirus cost the U.S. a median of $10.6 billion every year. Further, outbreaks that go unreported account for more than 90% of all the costs, according to the data.
Now what
Investors have been bidding up shares of Vaxart due to its efforts to develop a vaccine for COVID-19. But it seems its investigational norovirus vaccine also presents an exciting opportunity. Given the losses associated with this virus, Vaxart's candidate could go on to become a blockbuster product.
